Eton Pharmaceuticals, Inc. (ETON)
Automate Your Wheel Strategy on ETON
With Tiblio's Option Bot, you can configure your own wheel strategy including ETON - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ETON
- Rev/Share 1.7975
- Book/Share 0.9094
- PB 20.805
- Debt/Equity 0.0036
- CurrentRatio 1.9708
- ROIC -0.0394
- MktCap 507387100.0
- FreeCF/Share -0.0272
- PFCF -693.1518
- PE -110.9693
- Debt/Assets 0.001
- DivYield 0
- ROE -0.2341
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | ETON | H.C. Wainwright | -- | Buy | $17 | $33 | Jan. 23, 2025 |
| Initiation | ETON | B. Riley Securities | -- | Buy | -- | $21 | Jan. 10, 2025 |
| Reiterated | ETON | H.C. Wainwright | -- | Buy | $15 | $17 | Jan. 6, 2025 |
| Resumed | ETON | H.C. Wainwright | -- | Buy | -- | $9 | Sept. 4, 2024 |
News
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Published: May 29, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency.
Read More
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patients and investors. The model is already working well. ETON is able to execute on straightforward product improvements, and has the focus to educate specialist doctors on the need for these rare drugs.
Read More
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch –
Read More
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON's net sales.
Read More
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Read More
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.
Read More
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
About Eton Pharmaceuticals, Inc. (ETON)
- IPO Date 2018-11-13
- Website https://www.etonpharma.com
- Industry Biotechnology
- CEO Mr. Sean E. Brynjelsen
- Employees 31